18 research outputs found
Patient instruction and specific immunotherapy after severe anaphylaxis, stratified by general characteristics and reaction circumstances.
<p>SIT: Specific immunotherapy, ENT: Ear, nose and throat/Otolaryngology.</p
First time receiving prophylactic first aid drugs following severe anaphylaxis.
<p>First time receiving prophylactic first aid drugs following severe anaphylaxis.</p
Baseline characteristics and reaction circumstances of severe anaphylaxis patients treated by emergency physicians.
<p>Reported by emergency physicians in Berlin, Germany vs. self report in anaphylaxis registry.</p>*<p>comparable catchment areas, # only those initally treated by emergency physician.</p
Drugs used for emergency treatment of anaphylaxis, by cause.
<p>Only assured cases. All application routes, error bars indicate 95% confidence intervals.</p
Patients in anaphylaxis registry, first aid treatment stratified by general characteristics and reaction circumstances.
<p>Patients in anaphylaxis registry, first aid treatment stratified by general characteristics and reaction circumstances.</p
Drugs used by emergency physicians for initial treatment of anaphylaxis.
<p>Firsthand report (EPs) vs. self report (anaphylaxis registry). Parenteral application routes only. * Weighted for age, cause and severity distribution in anaphylaxis registry, Berlin catchment area.</p
Drugs used for emergency treatment of anaphylaxis, by age.
<p>Dashed lines indicate proportion of patients having received inhalation (adrenaline) or oral (antihistamine, corticoid) treatment only, error bars indicate 95% confidence intervals.</p
Circular dichroism of rBet v 1a/rBet v 1a<sub>S112P/R145P</sub> combinations.
<p>A) Circular dichroism of defined molar ratios of rBet v 1a/rBet v 1a<sub>S112P/R145P</sub>. 5 ÎĽM total rBet v 1a was measured with increasing fractions of rBet v 1a<sub>S112P/R145P</sub> from 0% to 100%. Mean residual ellipticities with 95% confidence interval and statistical evaluations at wave lengths 193 nm (B), 195 nm (C), 200 nm (D), 218 nm (E), and 222 nm (F) are shown.</p
Inhibition of IgE binding to immobilized rBet v 1a.
<p>Dose-dependent inhibition of IgE binding to surface-coated rBet v 1a by rBet v 1a/rBet v 1a<sub>S112P/R145P</sub> mixtures in the presence of increasing molar ratios of rBet v 1a<sub>S112P/R145P</sub> in ELISA. Curves were fitted in parallel with a 4-parameter, logistic sigmoidal curve fit with same slope, lower and upper asymptote for all curves.</p
Immunoglobulin binding of rBet v 1a and rBet v 1a<sub>S112P/R145P</sub>.
<p>Binding of IgE from sera of subjects allergic to birch pollen bound to purified (lane 14, Coomassie stain) rBet v 1a (upper panel) and rBet v 1a<sub>S112P/R145P</sub> (lower panel) (lanes 1–10). Binding of rabbit anti-Bet v 1 IgG to the rBet v 1a proteins is shown (lane 13). A minor degradation product of rBet v 1a<sub>S112P/R145P</sub> detected by IgG is shown (*). As controls, serum of non-allergic subject (lane 11) and buffer control (HRP-conjugated anti human IgE antibody only) (lane 12) were used.</p